These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 24297581

  • 1. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
    Salvaggio G, Furlan A, Agnello F, Cabibbo G, Marin D, Giannitrapani L, Genco C, Midiri M, Lagalla R, Brancatelli G.
    Radiol Med; 2014 Apr; 119(4):215-21. PubMed ID: 24297581
    [Abstract] [Full Text] [Related]

  • 2. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V.
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [Abstract] [Full Text] [Related]

  • 3. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL.
    Cancer; 2012 Jan 01; 118(1):147-56. PubMed ID: 21713764
    [Abstract] [Full Text] [Related]

  • 4. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
    Meyer T, Palmer DH, Cheng AL, Hocke J, Loembé AB, Yen CJ.
    Liver Int; 2017 Jul 01; 37(7):1047-1055. PubMed ID: 28066978
    [Abstract] [Full Text] [Related]

  • 5. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
    Tovoli F, Renzulli M, Negrini G, Brocchi S, Ferrarini A, Andreone A, Benevento F, Golfieri R, Morselli-Labate AM, Mastroroberto M, Badea RI, Piscaglia F.
    Eur Radiol; 2018 Sep 01; 28(9):3611-3620. PubMed ID: 29633000
    [Abstract] [Full Text] [Related]

  • 6. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W.
    BMC Res Notes; 2015 Oct 26; 8():609. PubMed ID: 26502722
    [Abstract] [Full Text] [Related]

  • 7. Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
    Patchett N, Furlan A, Marsh JW.
    Jpn J Clin Oncol; 2016 Sep 26; 46(9):839-44. PubMed ID: 27317737
    [Abstract] [Full Text] [Related]

  • 8. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S.
    Oncologist; 2014 Apr 26; 19(4):394-402. PubMed ID: 24652387
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
    Kaufmann S, Thaiss WM, Schulze M, Bitzer M, Lauer U, Nikolaou K, Horger M.
    Acta Radiol; 2018 Jul 26; 59(7):765-772. PubMed ID: 28927298
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
    Shiozawa K, Watanabe M, Kikuchi Y, Kudo T, Maruyama K, Sumino Y.
    World J Gastroenterol; 2012 Oct 28; 18(40):5753-8. PubMed ID: 23155317
    [Abstract] [Full Text] [Related]

  • 11. Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib.
    Corona-Villalobos CP, Halappa VG, Geschwind JF, Bonekamp S, Reyes D, Cosgrove D, Pawlik TM, Kamel IR.
    Eur Radiol; 2015 Feb 28; 25(2):380-90. PubMed ID: 25226843
    [Abstract] [Full Text] [Related]

  • 12. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
    Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, Miller FH, Yaghmai V, Abecassis M, Baker T, Mulcahy M, Nayar R, Lewandowski RJ, Salem R.
    Hepatology; 2013 Nov 28; 58(5):1655-66. PubMed ID: 23703789
    [Abstract] [Full Text] [Related]

  • 13. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
    Moschouris H, Malagari K, Gkoutzios P, Kalokairinou M, Stamatiou K, Chatzimichail K, Kornezos I, Karagiannis E, Kiltenis M, Papadaki MG.
    Med Ultrason; 2012 Jun 28; 14(2):87-94. PubMed ID: 22675707
    [Abstract] [Full Text] [Related]

  • 14. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Wang W, Bai W, Wang E, Zhao Y, Liu L, Yang M, Cai H, Xia D, Zhang L, Niu J, Yin Z, Zhang Z, Fan D, Xia J, Han G.
    Int J Cancer; 2017 Jan 15; 140(2):390-399. PubMed ID: 27681592
    [Abstract] [Full Text] [Related]

  • 15. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
    Arizumi T, Ueshima K, Takeda H, Osaki Y, Takita M, Inoue T, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    J Gastroenterol; 2014 Dec 15; 49(12):1578-87. PubMed ID: 24499826
    [Abstract] [Full Text] [Related]

  • 16. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Dai X, Schlemmer HP, Schmidt B, Höh K, Xu K, Ganten TM, Ganten MK.
    Eur J Radiol; 2013 Feb 15; 82(2):327-34. PubMed ID: 23246016
    [Abstract] [Full Text] [Related]

  • 17. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
    Mulé S, Thiefin G, Costentin C, Durot C, Rahmouni A, Luciani A, Hoeffel C.
    Radiology; 2018 Aug 15; 288(2):445-455. PubMed ID: 29584597
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Ippolito D, Querques G, Pecorelli A, Talei Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S.
    J Comput Assist Tomogr; 2019 Aug 15; 43(2):206-213. PubMed ID: 30407241
    [Abstract] [Full Text] [Related]

  • 19. CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib.
    Colagrande S, Calistri L, Campani C, Dragoni G, Lorini C, Nardi C, Castellani A, Marra F.
    Eur Radiol; 2021 Mar 15; 31(3):1608-1619. PubMed ID: 32827266
    [Abstract] [Full Text] [Related]

  • 20. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.
    Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM.
    Eur Radiol; 2021 May 15; 31(5):2737-2746. PubMed ID: 33123796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.